NCT00093210View on ClinicalTrials.gov

Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Study Completion Date

September 30, 2005

Conditions
Hemophilia B
Interventions
DRUG

rFIX

DRUG

rFIX-R

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00093210 - Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B | Biotech Hunter | Biotech Hunter